Want to see FR:ALMDT full AI Analyst Report?
Top Page
Median Technologies
(ALMDT)
Select Model
Select Model
Rating:46Neutral
Price Target:
€4.00
▼(-10.11% Downside)
Action:Reiterated
Date:08/29/26
The score is held down primarily by very weak financial performance: persistent large losses, negative gross profit in 2024–2025, ongoing operating cash burn, and negative equity that increases financing/dilution risk. Technicals are neutral with balanced momentum indicators, providing limited offset. Valuation is constrained by the negative P/E, signaling that profitability is not currently supporting the stock.
Positive Factors
Revenue Growth
Revenue growth accelerated materially in 2025 after modest expansion in 2024, indicating that demand for the company’s oncology imaging and AI offerings is developing. Continued top-line growth can improve operating leverage and create a stronger base for future commercialization.
Negative Factors
Persistent Losses
Persistent operating and net losses show that revenue growth has not yet translated into a sustainable earnings model. The very negative 2025 net margin leaves limited room for execution setbacks and means future progress depends on materially improving costs, pricing, or revenue mix.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Revenue growth accelerated materially in 2025 after modest expansion in 2024, indicating that demand for the company’s oncology imaging and AI offerings is developing. Continued top-line growth can improve operating leverage and create a stronger base for future commercialization.
Read all positive factors
Median Technologies (ALMDT) vs. iShares MSCI France ETF (EWQ)
Market Cap
€194.33M
Dividend YieldN/A
Average Volume (3M)138.94K
Price to Earnings (P/E)―
Beta (1Y)0.70
Revenue Growth1.79%
EPS Growth15.89%
CountryFR
Employees199
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.15
Shares Outstanding49,048,060
10 Day Avg. Volume96,603
30 Day Avg. Volume138,941
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)-4.95
Price to Sales (P/S)7.45
P/FCF Ratio-9.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.44
Revenue Forecast (FY)€26.25M
Median Technologies Business Overview & Revenue Model
Company Description
Headquartered in Valbonne, France, Median Technologies S.A. was established in 2002. This company specializes in developing and commercializing advanced software and platforms designed for medical image analysis. Its reach extends globally, servin...
How the Company Makes Money
Median Technologies primarily makes money through (1) imaging services and software provided to biopharmaceutical companies and clinical research organizations to support oncology drug development and clinical trials, and (2) commercialization of ...
Median Technologies Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
16
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 23.36M | 22.95M | 22.23M | 23.67M | 20.55M |
| Gross Profit | 24.05M | -21.07M | -2.55M | 24.42M | 20.43M |
| EBITDA | -25.13M | -19.28M | -19.59M | -17.48M | -17.10M |
| Net Income | -34.07M | -25.24M | -22.98M | -20.21M | -19.29M |
Balance Sheet | |||||
| Total Assets | 35.87M | 24.37M | 35.94M | 34.75M | 49.39M |
| Cash, Cash Equivalents and Short-Term Investments | 18.41M | 8.29M | 19.63M | 21.67M | 39.25M |
| Total Debt | 21.76M | 29.44M | 23.01M | 18.15M | 16.52M |
| Total Liabilities | 71.02M | 58.34M | 46.23M | 42.01M | 44.45M |
| Stockholders Equity | -35.15M | -33.97M | -10.29M | -7.25M | 4.94M |
Cash Flow | |||||
| Free Cash Flow | -18.17M | -19.03M | -21.53M | -17.18M | -10.61M |
| Operating Cash Flow | -17.43M | -17.95M | -20.24M | -15.79M | -10.13M |
| Investing Cash Flow | -824.00K | -1.17M | -1.25M | -1.39M | -672.00K |
| Financing Cash Flow | 28.43M | 7.67M | 19.72M | -277.00K | 33.20M |
Median Technologies Technical Analysis
Negative
4.45
Price Trends
4.32
Negative
4.70
Negative
4.57
Negative
Market Momentum
-0.11
Positive
31.59
Neutral
6.97
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALMDT, the sentiment is Negative. The current price of 4.45 is above the 20-day moving average (MA) of 4.37, above the 50-day MA of 4.32, and below the 200-day MA of 4.57, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 31.59 is Neutral, neither overbought nor oversold. The STOCH value of 6.97 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALMDT.
Median Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | €199.61M | 40.85 | 2.71% | ― | 9.08% | 21.19% | |
48 Neutral | €31.13M | 7.71 | -58.93% | ― | 7.43% | ― | |
47 Neutral | €51.34M | -6.29 | 222.05% | ― | 42.86% | 13.93% | |
46 Neutral | €194.33M | -3.44 | 90.10% | ― | 1.79% | 15.89% | |
46 Neutral | €22.10M | -5.13 | -22.03% | ― | 37.28% | 7.83% |
* Healthcare Sector Average
FR:ALMDT
Median Technologies
3.96
0.61
18.21%
FR:ALMKT
MAUNA KEA TECHNOLOGIES
0.16
0.05
50.00%
FR:ALTHE
Theraclion SA
0.69
-0.01
-2.00%
FR:ALERS
Eurobio-Scientific SA
19.20
-6.05
-23.96%
FR:ALDMS
Diagnostic Medical Systems
0.99
-0.36
-26.79%
FR:ALIKO
Ikonisys SA
1.40
-0.12
-7.89%
Median Technologies Corporate Events
Median Technologies sets H1 2026 earnings date and intensifies investor outreach
Sep 10, 2026
Median Technologies has outlined its upcoming financial communication schedule, stating that its H1 2026 results will be released after market close on October 29, 2026. The announcement provides investors with visibility on the next key financial...
Median Technologies Updates Capital Structure and Outstanding Warrants
Sep 8, 2026
Median Technologies disclosed updated capital and voting rights data, reporting a share capital composed of 49,071,263 shares and an actual voting rights count of 49,002,485, alongside a theoretical voting rights total of 49,048,063. The company a...
Median Technologies launches strategic review to unlock value in AI oncology businesses
Sep 2, 2026
Median Technologies’ board has launched a Strategic Review Committee to examine structural, transactional and financing options, including a possible separation of its iCRO unit from the eyonis® medical device business and a potential U...
Median Technologies Updates Share Capital and Warrants in Regulatory Filing
Aug 10, 2026
Median Technologies has disclosed its latest capital structure and voting rights data, reporting a total of 49,071,263 shares outstanding. The company lists 49,011,540 real voting rights, with a slightly higher theoretical voting rights figure tha...
Median Technologies strikes global Canon partnership to scale AI lung cancer screening
Jul 30, 2026
Median Technologies has signed a global strategic commercial partnership with Canon Medical Systems, through its subsidiary Olea Medical, to accelerate deployment of its eyonis Lung Cancer Screening AI software across the U.S., Europe and addition...
Median Technologies strengthens finances as eyonis lung cancer AI wins U.S. and EU approval
Jul 22, 2026
Median Technologies, a specialist in AI-based medical imaging software and central imaging services for oncology trials, is deepening its presence in cancer screening and clinical research markets. The company’s eyonis® suite, initially...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.